Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight candida species and the CLSI M27-A3 broth microdilution method

M. A. Pfaller, A. Espinel-Ingroff, B. Bustamante, E. Canton, D. J. Diekema, A. Fothergill, J. Fuller, G. M. Gonzalez, J. Guarro, C. Lass-Flörl, S. R. Lockhart, E. Martin-Mazuelos, J. F. Meis, L. Ostrosky-Zeichner, T. Pelaez, G. St-Germain, J. Turnidge

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Since epidemiological cutoff values (ECVs) using CLSI MICs from multiple laboratories are not available for Candida spp. and the echinocandins, we established ECVs for anidulafungin and micafungin on the basis of wild-type (WT) MIC distributions (for organisms in a species-drug combination with no detectable acquired resistance mechanisms) for 8,210 Candida albicans, 3,102 C. glabrata, 3,976 C. parapsilosis, 2,042 C. tropicalis, 617 C. krusei, 258 C. lusitaniae, 234 C. guilliermondii, and 131 C. dubliniensis isolates. CLSI broth microdilution MIC data gathered from 15 different laboratories in Canada, Europe, Mexico, Peru, and the United States were aggregated to statistically define ECVs. ECVs encompassing 97.5% of the statistically modeled population for anidulafungin and micafungin were, respectively, 0.12 and 0.03 μg/ml for C. albicans, 0.12 and 0.03 μg/ml for C. glabrata, 8 and 4 μg/ml for C. parapsilosis, 0.12 and 0.06 μg/ml for C. tropicalis, 0.25 and 0.25 g/ml for C. krusei, 1 and 0.5 μg/ml for C. lusitaniae, 8 and 2 μg/ml for C. guilliermondii, and 0.12 and 0.12 μg/ml for C. dubliniensis. Previously reported single and multicenter ECVs defined in the present study were quite similar or within 1 2-fold dilution of each other. For a collection of 230 WT isolates (no fks mutations) and 51 isolates with fks mutations, the species-specific ECVs for anidulafungin and micafungin correctly classified 47 (92.2%) and 51 (100%) of the fks mutants, respectively, as non-WT strains. These ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin and micafungin due to fks mutations.

Original languageEnglish (US)
Pages (from-to)916-922
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

anidulafungin
Candida
Multicenter Studies
Candida albicans
Mutation
Echinocandins
Peru
Drug Combinations
Mexico
Canada
micafungin
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight candida species and the CLSI M27-A3 broth microdilution method. / Pfaller, M. A.; Espinel-Ingroff, A.; Bustamante, B.; Canton, E.; Diekema, D. J.; Fothergill, A.; Fuller, J.; Gonzalez, G. M.; Guarro, J.; Lass-Flörl, C.; Lockhart, S. R.; Martin-Mazuelos, E.; Meis, J. F.; Ostrosky-Zeichner, L.; Pelaez, T.; St-Germain, G.; Turnidge, J.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 2, 02.2014, p. 916-922.

Research output: Contribution to journalArticle

Pfaller, MA, Espinel-Ingroff, A, Bustamante, B, Canton, E, Diekema, DJ, Fothergill, A, Fuller, J, Gonzalez, GM, Guarro, J, Lass-Flörl, C, Lockhart, SR, Martin-Mazuelos, E, Meis, JF, Ostrosky-Zeichner, L, Pelaez, T, St-Germain, G & Turnidge, J 2014, 'Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight candida species and the CLSI M27-A3 broth microdilution method', Antimicrobial Agents and Chemotherapy, vol. 58, no. 2, pp. 916-922. https://doi.org/10.1128/AAC.02020-13
Pfaller, M. A. ; Espinel-Ingroff, A. ; Bustamante, B. ; Canton, E. ; Diekema, D. J. ; Fothergill, A. ; Fuller, J. ; Gonzalez, G. M. ; Guarro, J. ; Lass-Flörl, C. ; Lockhart, S. R. ; Martin-Mazuelos, E. ; Meis, J. F. ; Ostrosky-Zeichner, L. ; Pelaez, T. ; St-Germain, G. ; Turnidge, J. / Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight candida species and the CLSI M27-A3 broth microdilution method. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 2. pp. 916-922.
@article{16cf9dbdb8e0428c858981c15c8c686d,
title = "Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight candida species and the CLSI M27-A3 broth microdilution method",
abstract = "Since epidemiological cutoff values (ECVs) using CLSI MICs from multiple laboratories are not available for Candida spp. and the echinocandins, we established ECVs for anidulafungin and micafungin on the basis of wild-type (WT) MIC distributions (for organisms in a species-drug combination with no detectable acquired resistance mechanisms) for 8,210 Candida albicans, 3,102 C. glabrata, 3,976 C. parapsilosis, 2,042 C. tropicalis, 617 C. krusei, 258 C. lusitaniae, 234 C. guilliermondii, and 131 C. dubliniensis isolates. CLSI broth microdilution MIC data gathered from 15 different laboratories in Canada, Europe, Mexico, Peru, and the United States were aggregated to statistically define ECVs. ECVs encompassing 97.5{\%} of the statistically modeled population for anidulafungin and micafungin were, respectively, 0.12 and 0.03 μg/ml for C. albicans, 0.12 and 0.03 μg/ml for C. glabrata, 8 and 4 μg/ml for C. parapsilosis, 0.12 and 0.06 μg/ml for C. tropicalis, 0.25 and 0.25 g/ml for C. krusei, 1 and 0.5 μg/ml for C. lusitaniae, 8 and 2 μg/ml for C. guilliermondii, and 0.12 and 0.12 μg/ml for C. dubliniensis. Previously reported single and multicenter ECVs defined in the present study were quite similar or within 1 2-fold dilution of each other. For a collection of 230 WT isolates (no fks mutations) and 51 isolates with fks mutations, the species-specific ECVs for anidulafungin and micafungin correctly classified 47 (92.2{\%}) and 51 (100{\%}) of the fks mutants, respectively, as non-WT strains. These ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin and micafungin due to fks mutations.",
author = "Pfaller, {M. A.} and A. Espinel-Ingroff and B. Bustamante and E. Canton and Diekema, {D. J.} and A. Fothergill and J. Fuller and Gonzalez, {G. M.} and J. Guarro and C. Lass-Fl{\"o}rl and Lockhart, {S. R.} and E. Martin-Mazuelos and Meis, {J. F.} and L. Ostrosky-Zeichner and T. Pelaez and G. St-Germain and J. Turnidge",
year = "2014",
month = "2",
doi = "10.1128/AAC.02020-13",
language = "English (US)",
volume = "58",
pages = "916--922",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight candida species and the CLSI M27-A3 broth microdilution method

AU - Pfaller, M. A.

AU - Espinel-Ingroff, A.

AU - Bustamante, B.

AU - Canton, E.

AU - Diekema, D. J.

AU - Fothergill, A.

AU - Fuller, J.

AU - Gonzalez, G. M.

AU - Guarro, J.

AU - Lass-Flörl, C.

AU - Lockhart, S. R.

AU - Martin-Mazuelos, E.

AU - Meis, J. F.

AU - Ostrosky-Zeichner, L.

AU - Pelaez, T.

AU - St-Germain, G.

AU - Turnidge, J.

PY - 2014/2

Y1 - 2014/2

N2 - Since epidemiological cutoff values (ECVs) using CLSI MICs from multiple laboratories are not available for Candida spp. and the echinocandins, we established ECVs for anidulafungin and micafungin on the basis of wild-type (WT) MIC distributions (for organisms in a species-drug combination with no detectable acquired resistance mechanisms) for 8,210 Candida albicans, 3,102 C. glabrata, 3,976 C. parapsilosis, 2,042 C. tropicalis, 617 C. krusei, 258 C. lusitaniae, 234 C. guilliermondii, and 131 C. dubliniensis isolates. CLSI broth microdilution MIC data gathered from 15 different laboratories in Canada, Europe, Mexico, Peru, and the United States were aggregated to statistically define ECVs. ECVs encompassing 97.5% of the statistically modeled population for anidulafungin and micafungin were, respectively, 0.12 and 0.03 μg/ml for C. albicans, 0.12 and 0.03 μg/ml for C. glabrata, 8 and 4 μg/ml for C. parapsilosis, 0.12 and 0.06 μg/ml for C. tropicalis, 0.25 and 0.25 g/ml for C. krusei, 1 and 0.5 μg/ml for C. lusitaniae, 8 and 2 μg/ml for C. guilliermondii, and 0.12 and 0.12 μg/ml for C. dubliniensis. Previously reported single and multicenter ECVs defined in the present study were quite similar or within 1 2-fold dilution of each other. For a collection of 230 WT isolates (no fks mutations) and 51 isolates with fks mutations, the species-specific ECVs for anidulafungin and micafungin correctly classified 47 (92.2%) and 51 (100%) of the fks mutants, respectively, as non-WT strains. These ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin and micafungin due to fks mutations.

AB - Since epidemiological cutoff values (ECVs) using CLSI MICs from multiple laboratories are not available for Candida spp. and the echinocandins, we established ECVs for anidulafungin and micafungin on the basis of wild-type (WT) MIC distributions (for organisms in a species-drug combination with no detectable acquired resistance mechanisms) for 8,210 Candida albicans, 3,102 C. glabrata, 3,976 C. parapsilosis, 2,042 C. tropicalis, 617 C. krusei, 258 C. lusitaniae, 234 C. guilliermondii, and 131 C. dubliniensis isolates. CLSI broth microdilution MIC data gathered from 15 different laboratories in Canada, Europe, Mexico, Peru, and the United States were aggregated to statistically define ECVs. ECVs encompassing 97.5% of the statistically modeled population for anidulafungin and micafungin were, respectively, 0.12 and 0.03 μg/ml for C. albicans, 0.12 and 0.03 μg/ml for C. glabrata, 8 and 4 μg/ml for C. parapsilosis, 0.12 and 0.06 μg/ml for C. tropicalis, 0.25 and 0.25 g/ml for C. krusei, 1 and 0.5 μg/ml for C. lusitaniae, 8 and 2 μg/ml for C. guilliermondii, and 0.12 and 0.12 μg/ml for C. dubliniensis. Previously reported single and multicenter ECVs defined in the present study were quite similar or within 1 2-fold dilution of each other. For a collection of 230 WT isolates (no fks mutations) and 51 isolates with fks mutations, the species-specific ECVs for anidulafungin and micafungin correctly classified 47 (92.2%) and 51 (100%) of the fks mutants, respectively, as non-WT strains. These ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin and micafungin due to fks mutations.

UR - http://www.scopus.com/inward/record.url?scp=84893467170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893467170&partnerID=8YFLogxK

U2 - 10.1128/AAC.02020-13

DO - 10.1128/AAC.02020-13

M3 - Article

C2 - 24277027

AN - SCOPUS:84893467170

VL - 58

SP - 916

EP - 922

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -